Kenvue Inc. (NYSE:KVUE) Shares Bought by Drystone LLC

Drystone LLC grew its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 60.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 154,857 shares of the company's stock after purchasing an additional 58,267 shares during the period. Kenvue makes up about 3.7% of Drystone LLC's holdings, making the stock its 13th largest holding. Drystone LLC's holdings in Kenvue were worth $3,713,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Fulton Bank N.A. increased its holdings in Kenvue by 0.6% in the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company's stock valued at $1,892,000 after buying an additional 465 shares during the last quarter. Scott & Selber Inc. increased its holdings in Kenvue by 0.4% in the first quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock valued at $2,557,000 after buying an additional 475 shares during the last quarter. Keystone Financial Group increased its holdings in Kenvue by 4.8% in the fourth quarter. Keystone Financial Group now owns 12,736 shares of the company's stock valued at $272,000 after buying an additional 578 shares during the last quarter. Transatlantique Private Wealth LLC grew its holdings in shares of Kenvue by 5.7% during the fourth quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company's stock worth $228,000 after purchasing an additional 580 shares during the last quarter. Finally, Byrne Asset Management LLC grew its holdings in shares of Kenvue by 1.0% during the first quarter. Byrne Asset Management LLC now owns 63,467 shares of the company's stock worth $1,522,000 after purchasing an additional 621 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $21.35 on Friday. The business's 50 day simple moving average is $22.34 and its 200-day simple moving average is $22.29. The firm has a market capitalization of $40.96 billion, a price-to-earnings ratio of 38.82, a price-to-earnings-growth ratio of 3.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. Kenvue Inc. has a 12 month low of $17.85 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period in the previous year, the firm posted $0.28 EPS. The company's quarterly revenue was down 3.9% compared to the same quarter last year. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.84%. Kenvue's dividend payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KVUE. Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective on the stock. Redburn Atlantic assumed coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. UBS Group increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Finally, Barclays increased their target price on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Monday, May 12th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.